You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美国药厂Moderna冀新冠疫苗测试下月取得中期结果 赶及申请年内紧急认证使用
阿思达克 10-21 10:10
《华尔街日报》报道,研发新冠疫苗的美国药厂Moderna(MRNA.US)行政总裁Stephane Bancel表示,如果该公司的大规模临床试验在11月份获得积极的中期结果,美国联邦政府或会在12月批准该公司新冠疫苗作紧急使用。他亦指,若要就测试疫苗获得足够中期研究结果,便需要更长的时间,疫苗或要到明年初才会获得政府批准。

报道指,首次中期结果需要有53名志愿者出现新冠病徵才能得出。Bancel称难以预何时得到中期结果,因这视乎发病个案及有多少人染病。Bancel早前接受英国《金融时报》访问时表示,预计在11月25日前未能就批准新冠疫苗作紧急使用提出申请。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account